Date post: | 15-Jan-2016 |
Category: |
Documents |
Upload: | leon-mortimore |
View: | 215 times |
Download: | 0 times |
© Copyright 2014 by K&L Gates LLP. All rights reserved.
FDA UPDATE: Essential Knowledge Pharmaceutical and Medical Device Companies Need for 2015
All Hands Meeting - November 6-7, 2014
Presenters:
Ellen Darling
+1.949.623.3540
Carol Pratt
+1.503.226.5762
Agenda FDA Guidance on Social Media/Advertisements New Preemption Implications Proposed Regulation of Software Used in
Healthcare IT Mobile medical applications, medical device
data systems, medical image storage/communication devices
Proposed Regulation of Laboratory Developed Tests
klgates.com 2
FDA Guidance on Social Media/Advertisements
klgates.com
FDA Guidance on Social Media/Advertisements
Evolution of Direct-to-Consumer (“DTC”) Advertising
Before 1906, there were no regulations relating to the marketing of drugs.
A drug company, or really anyone, could concoct crazy formulas, patent them and say anything they
wanted about their invention.
klgates.com 4
Evolution of DTC Advertising
klgates.com 5
Evolution of DTC Advertising
By the mid-1980’s, the FDA declared that it had regulatory jurisdiction over DTC ads and required, among other things:
A fair and balanced account of risks and benefits
A summary of potential side effects
klgates.com 6
Evolution of DTC Advertising
Meeting these requirements in print ads was do-able, but accomplishing this in radio and TV ads posed problems for the industry.
As a result, companies started relying more on other types of ads as a way to get around the rules:
Reminder Ad Help-Seeking Ad
klgates.com 7
Evolution of DTC Advertising
Traditional DTC advertising is expensive. In 2007, industry spent $5 billion on DTC ads.
DTC advertising is controversial. Opponents argue:
Leaves patients misinformed and sometimes overwhelmed
Overemphasizes the benefits of the drug Leads to over-utilization of drugs Short-circuits important discussions between a
patient and a physician
klgates.com 8
Evolution of DTC Advertising
Proponents argue: Helps educate patients about different medical
conditions and drug therapies Causes them to do more research about a
potential condition or drug option More likely to reach out to their doctors with
questions
klgates.com 9
Evolution of DTC Advertising
Our research indicates that only two countries, the U.S. and New Zealand, allow DTC advertising.
klgates.com 10
DTC Ads Via Social Media
Our industry has been relatively slow to utilize social media despite statistics about the number of:
People with multiple devices using social media every day
Facebook comments every minute Tweets generated weekly
This form of advertising is inexpensive compared to traditional, DTC advertising.
So why the delay?
klgates.com 11
DTC Ads Via Social Media
November 2009 - FDA held a hearing entitled “Promotion of Food and Drug Administration - Regulated Medical Products Using the Internet and Social Media Tools” to discuss, among other things:
What online communications are manufacturers, packers and distributors accountable for?
How can manufacturers, packers and/or distributors fulfill regulatory requirements (e.g., fair balance, disclosure information, and post-marketing submission requirements) in their internet and social media promotion?
When is the use of links appropriate?
klgates.com 12
DTC Ads Via Social Media
What happened after the FDA hearing in 2009?
The FDA initially received over 70 comments to the docket
In 2009 alone, FDA issued over a dozen warning letters relating to promotion on social media
klgates.com 13
June 2014 Notice of Draft Guidance
klgates.com 14
June 2014 Notice of Draft Guidance
The FDA states:
“This draft guidance is intended to describe FDA’s current thinking about how manufacturers, packers, and distributors . . . of prescription human and animal drugs . . . and medical devices for human use . . . that choose to present benefit information should present both benefit and risk information within advertising and promotional labeling . . . of their FDA-regulated medical products on
electronic/digital platforms that are associated with character space limitations—specifically on the
Internet and through social media or other technological venues (Internet/social media)….”
klgates.com 15
June 2014 Notice of Draft Guidance
The FDA continues:
“..Examples of Internet/social media platforms with character space limitations include online microblog messaging (e.g., messages on Twitter or “tweets,” which are currently limited to 140 character spaces per tweet) and online paid search (e.g., “sponsored links” on search engines such as Google and Yahoo, which have limited character spaces as well as other platform-imposed considerations.”
klgates.com 16
June 2014 Notice of Draft Guidance
The FDA stated that the general factors that should be considered in communicating benefit information on Internet/social media with character space limitations are:
“Benefit information should be accurate and non-misleading and reveal material facts within each individual character-space-limited communication (e.g., each individual message or tweet).” Reveal material facts about the use of a
product, such as limitations to an indication or the relevant patient population
klgates.com 17
June 2014 Notice of Draft Guidance
“Benefit information should be accompanied by risk information within each individual character-space-limited communication.”
A company must assess whether, once benefit information is conveyed, there is enough room to “adequately convey required risk information” and any other required information
Should communicate the most serious risks Provide a mechanism (i.e., a hyperlink) to allow direct
and exclusive access to a complete discussion of only the risks of the product
klgates.com 18
June 2014 Notice of Draft Guidance
What does the FDA say a company should do if it cannot fit all of this information in 140 characters?
Do not do it - consider some other mode of advertising
klgates.com 19
What Did Industry Think About The Draft Guidance?
FDA’s guidance is contrary to its own conduct Does not take into consideration certain search
engines, such as Google, that state that there is no guarantee that links will be displayed
Precludes, as written, manufacturers, etc… of complex drugs with multiple indications and serious risks, or certainly boxed warnings, from using this form of advertising
FDA should consider following a guideline similar to the FTC’s social media guideline
Violates the First Amendment
klgates.com 20
September 2014 Notice of Draft Guidance
klgates.com 21
DTC Ads Via Social Media – Risks and Benefits
Managing decisions relating to whether to advertise via the Internet/social media Risks of advertising on social media:
Warning letters Lack of control over re-tweets etc… Litigation with competitors Loss of control of messaging and brand image Costs associated with monitoring and other
regulatory issues
klgates.com 22
DTC Ads Via Social Media – Risks and Benefits
Potential benefits of advertising on social media:
Statistics about social media’s effect on buying/decision making
Increase market share? Reminder ads are not as impactful as product
claim ads Sheer increase in the number of your potential
audience Less expensive than traditional DTC ads
klgates.com 23
New Preemption Implications
Impact of Preemption Decisions and the FDA’s 2013 Proposal
Wyeth v. Levine, 555 U.S. 555 (2009)
A state-law failure to warn tort action against a brand name drug manufacturer is not preempted.
PLIVA Inc. v. Mensing, 131 S. Ct. 2567 (2011)
FDA’s regulations preventing generic drug manufacturers from changing their labeling except to mirror the label of the brand-name manufacturer preempt state-law failure-to-warn claims against generic drug manufacturers because it is impossible for generic drug manufacturers to comply with both federal and state duties to warn.
klgates.com 25
Impact of Preemption Decisions and the FDA’s 2013 Proposal
Mutual Pharm. Co., Inc. v. Barlett, 133 S. Ct. 2466 (2013)
State-law design defect claims that turn on the adequacy of a drug’s warnings are preempted by the FDC Act and under Mensing.
klgates.com 26
Impact of Preemption Decisions and the FDA’s 2013 Proposal
klgates.com 27
Impact of Preemption Decisions and the FDA’s 2013 Proposal
klgates.com 28
FDA’s Proposal – The Aftermath
FDA’s proposal spawned numerous comments and criticisms:
Several Republican members of Congress expressed “grave concerns” in a letter to FDA Commissioner Hamburg, M.D.:
Proposal conflicts directly with the statuteThwarts the law’s purpose and objectivesImposes significant costs on the drug industry and consumersGeneric Pharmaceutical Association’s concerns:The proposal is unjustified and unwarrantedThe proposal, if allowed, would result in an estimated $4 billion in U.S. health care costs annuallyUnintended consequences affecting patient’s access to drug therapies
FDA’s response to the criticismklgates.com 29
FDA’s Proposal – The Aftermath
Views of the supporters of the proposal:Will allow the public to be informed as soon as possible when new safety information becomes availableAssure labeling for a prescription drug remains up-to-date when the branded drug is no longer being marketedHelps incentivize generic drug manufacturers concerns about tort liability
klgates.com 30
The Dolin Decision
Can a brand manufacturer be held liable to a plaintiff for injuries and/or death allegedly caused by ingestion of a drug manufactured and sold by a generic company. Yes.
Dolin v. Smithkline Beecham Corp., 2013 U.S. Dist. LEXIS 3211 | 2013 WL 120279
Patient only ingested generic versionNegligence causes of action allowed to standCauses of action that could not standCourt’s reasoning
klgates.com 31
Impact on the Generic and Brand Industry
Safety department’s evolving role
Monitoring adverse events of other companies
Management of new labeling issues
klgates.com 32
Proposed Regulation of Software Used in Healthcare IT
Congressional Mandate to FDAExplosion of Health IT
Lack of coherent FDA regulatory framework uncertainty in industry (interferes with innovation)
Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012
Required FDA to develop and post on its website a proposed strategy and recommendations on: An appropriate, risk-based regulatory framework
for healthcare information technology that:
Promotes innovation Protects patient safety, and Avoids regulatory duplication
klgates.com 34
Congressional Mandate - FDASIA
FDA required to develop strategy and recommendations with federal partners:
Office of the National Coordinator for Health Information Technology (ONC)
Federal Communications Commission (FCC)
April 2014 – FDASIA Health IT Report “Proposed Strategy and Recommendations
for a Risk-Based Framework” Authored by FDA, ONC and FCC
klgates.com 35
April 2014 – FDASIA Health IT Report
klgates.com 36
FDASIA Health IT Report – April 2014
Three Categories of Health IT Functionality
1. Administrative Health IT Billing, claims processing, scheduling, etc.
2. Health Management Health IT Health information and data management, data
capture and encounter documentation, electronic access to clinical results, most clinical decision support software
3. Health IT with Medical Device Functionality An instrument, apparatus, implement, machine …
including any component, part, or accessory, which is … intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease”
klgates.com 37
FDASIA Health IT Report – April 2014
Health IT with Medical Device Functionality Current focus of FDA oversightRegulate under FDA’s current regulatory framework for medical devices
If Health IT meets statutory definition of a “medical device,” then subject to FDA oversight
No need for new statutory category or regulations – can regulated under existing medical device framework
klgates.com 38
FDASIA Health IT Report – April 2014
Principles for Regulatory Framework Narrowly tailored approach to FDA regulation of Health IT
Recognizes limited FDA resources Oversight driven by patient risk
Employ a risk-based approach to appropriately mitigate patient safety risks while avoiding unnecessary regulatory oversight
Medical devices: Class I, II, IIILeverage industry standards and best practicesFacilitate innovation
klgates.com 39
September 2013 Notice of Draft Guidance
klgates.com 40
What’s New? FDA Regulation of Healthcare IT
Mobile Medical Applications – DRAFT Guidance (6/25/13)
“Mobile application” Software that runs on a mobile platform, or Web-based software executed on a server but
tailored to a mobile platform FDA will focus regulatory oversight on mobile
medical apps that are “medical devices” and could pose risk to patient safety if the mobile
app did not function as intended
klgates.com 41
FDA Regulation of Medical Devices Class I devices: General Controls
Establishment registration and medical device listing
Quality System (QS) regulation Labeling requirements Medical Device Reporting Premarket notification - 510(k) (unless exempt) Reporting Corrections and Removals
Class II devices: General Controls + Special Controls + (usually) Premarket Notification (510(k))
Class III devices: General Controls + Premarket Approval (PMA)
klgates.com 42
FDA Regulation of Mobile Medical AppsFDA intends to exercise enforcement discretion on
low risk software intended to: Help patients self-manage their disease or conditions without
providing specific treatment or treatment suggestions Provide patients with simple tools to organize and track their
health information Provide easy access to information related to patients’ health
conditions or treatments Help patients document, show, or communicate potential
medical conditions to health care providers Automate simple tasks for health care providers Enable patients or providers to interact with Personal Health
Record (PHR) or Electronic Health Record (EHR) systems.
klgates.com 43
FDA Regulation of Mobile Medical AppsExamples of apps for which FDA intends to exercise Enforcement
Discretion Allow asthmatics to track inhaler usage, asthma attacks, location of user at
the time of an attack, or environmental triggers of attacks Provide periodic educational information, reminders, or motivational
guidance to smokers trying to quit, patients recovering from addiction, or pregnant women
Enable a patient or caregiver to create and send an alert or general emergency notification to first responders
Allow a user to collect (electronically or manually entered) blood pressure data and share this data through e-mail, track and trend it, or upload it to a personal or electronic health record
Allow user to log, record, track, evaluate, or make decisions or behavioral suggestions related to developing or maintaining general fitness, health or wellness
klgates.com 44
FDA Regulation of Mobile Medical Apps
FDA will enforce compliance on mobile medical apps that: Connect to one or more medical devices for the purpose of
controlling the device(s) or displaying, storing, analyzing, or transmitting patient-specific medical device data
Transform the mobile platform (hand held) into a regulated medical device by using attachments, display screens, or sensors or by including functionalities similar to those of currently regulated medical devices
Perform patient-specific analysis and providing patient-specific diagnosis, or treatment recommendations
klgates.com 45
Examples of Mobile Medical Apps That Must Meet Regulatory Requirements
Mobile medical apps that connect to existing medical devices to control the device(s) or display, store, analyze, or transmit patient-specific, including apps that:
alter the function/settings of an infusion pump control or change settings of an implantable
neuromuscular stimulator calibrate, control, or change settings of a cochlear
implant act as wireless remote controls or synchronization
devices for computed tomography (CT) or X-Ray machines
klgates.com 46
Examples of Mobile Medical Apps That Must Meet Regulatory Requirements
Mobile medical apps that transform a mobile platform into a medical device, including apps that:
use a sensor or lead connected to a mobile platform to measure and display the electrical signal produced by the heart (electrocardiograph or ECG) or blood glucose levels
use tools within the mobile platform (e.g., speaker) to produce controlled levels of test tones and signals intended for use in conducting diagnostic hearing evaluations
use an attachment to the mobile platform (e.g., light source, laser) to treat acne, reduce wrinkles, or remove hair
klgates.com 47
Examples of Mobile Medical Apps That Must Meet Regulatory Requirements
Mobile medical apps that perform patient-specific analysis and providing patient-specific diagnosis, or treatment recommendations, including apps that:
connect to a nursing central station and display medical device data to a physician’s mobile platform for review (e.g., a medical device data system)
connect to a perinatal monitoring system and transfer uterine contraction and fetal heart rate data to another display to allow for remote monitoring of labor progress
connect to bedside (or cardiac) monitors and transfer the data to a central viewing station for display and active patient monitoring
klgates.com 48
June 2014 – FDA Expands Enforcement Discretion of Health IT
klgates.com 49
June 2014 DRAFT Guidance
FDA expanded scope of Health IT devices subject to FDA’s enforcement discretionThree categories of medical devices
Medical device data systems (MDDS) [21 CFR 880.6310]
Medical image storage device [21 CFR 892.2010]
Medical image communications device [21 CFR 892.2020]
klgates.com 50
Medical Image Devices
Medical image storage device Provides electronic storage and retrieval
functions for medical images
Medical image communications device Provides electronic transfer of medical image
data between medical devices
klgates.com 51
Medical Device Data Systems (MDDS)
MDDS are:
Hardware or software products That transfer, store, convert formats, and
display medical device data Do not modify the data Do not control the functions or parameters of
any connected medical device Are not intended to be used in connection with
active patient monitoring
klgates.com 52
Medical Device Data Systems (MDDS) February 2011 – FDA down-classified from
class III (PMA) to class I (general controls) June 2014 – FDA does not intend to enforce
any regulatory requirements “This means that for [these] devices …, the
FDA does not intend to enforce compliance with the regulatory controls, including registration and listing, premarket review, postmarket reporting and quality system regulation for manufacturers of these types of devices.”
Applies also to mobile medical apps that are MDDS
klgates.com 53
FDA Regulation of Health IT – Practice Tips
Know whether your software is/is not a medical device Subject to FDA’s enforcement discretion? Subject to FDA’s medical device requirements?
Set limits on functionality Even class I medical devices require more time and $$ to
develop Monitor upgrades & improvements
Ensure marketing claims/strategy are consistent with intended regulatory category Monitor ‘claims creep’
Watch for FDA to finalize guidances FDA is regulating by guidances, not formal rulemaking
klgates.com 54
Proposed Regulation of Laboratory Developed Tests
Proposed Regulation of Laboratory Developed Tests (LDTs)
What is an LDT? An in vitro diagnostic (IVD) that is intended for
clinical use and designed, manufactured and used within a single laboratory Made and used by the same lab Device is not sold; test results are sold
Also known as “home brew” assays or devicesIVDs are included in the FDA definition of medical device
FDA has exercised enforcement discretion for LDTs since 1976
klgates.com 56
Proposed Regulation of LDTs LDTs have been regulated by CLIA since 1988
CLIA requirements focus on testing process – ability to perform test in an accurate and reliable manner
FDA has been asserting the need for more FDA regulation of LDTs for several years LDTs have evolved from “traditional” LDTs
Typically manufactured in small volumes by local labs
Used commercially available components, legally marketed for clinical use
Were interpreted by physicians and pathologists at treating facility
klgates.com 57
Proposed Regulation of LDTs
Modern LDTs are: manufactured with components that are not legally
marketed for clinical use and/or not made by the testing lab offered beyond local populations and manufactured in high
volume used widely to screen for common diseases rather than
rare diseases used to direct critical treatment decisions (e.g., prediction of
drug response) highly complex (e.g., automated interpretation, multi-signal
devices, use of non-transparent algorithms and/or complex software to generate device results)
klgates.com 58
October 3, 2014 FDA Proposed Regulation of LDTs
2 Draft Guidances
klgates.com 59
LDT Framework Guidance
Rationale for FDA regulation of LDTs FDA regulation of safety and efficacy needed to fill
gaps in CLIA oversight Clinical validity
Accuracy of test to measure or detect the clinical condition for which it is intended
Analytical validity Analytical specificity and sensitivity,
accuracy and precision Not evaluated by CLIA before test is used
Post-market surveillance Adverse event reporting
klgates.com 60
LDT Framework Guidance – Proposed Regulation
Continued full enforcement discretion
LDTs for forensic use LDTs used in CLIA-certified, high-
complexity histocompatibility laboratories for organ, stem cell, and tissue transplantation
klgates.com 61
LDT Framework Guidance – Proposed Regulation
Partial enforcement discretion Regulatory requirements
Yes - General controls, registration & listing, AE reporting
No - premarket review, QS Applies to:
Low-risk (class I) LDTs LDTs for rare diseases “Traditional” LDTs LDTs for Unmet Needs” when no FDA-
approved or cleared equivalent device is available
klgates.com 62
LDT Framework Guidance – Proposed Regulation
No enforcement discretion Requirements: premarket review, QS,
registration & listing, AE reporting Moderate risk (class II) LDTs
510(k) FDA aims to use third party review for
premarket review High risk (class III) LDTs
PMA FDA will do premarket review
klgates.com 63
LDT Framework Guidance – Proposed Regulation
Classification of LDTs Risk based FDA will use expert advisory panels Factors (not exclusive list)
Level of risk of disease/condition or patient population
Screening or diagnosis use Nature of the clinical decision based on the test result Other data available to MD (in addition to the LDT
result), Potential consequences/impact of erroneous results
FDA will issue draft guidance within 18 months of finalizing Framework Guidance
klgates.com 64
LDT Framework Guidance – Timelines
klgates.com
Requirement Class After Final Guidance
Registration & Listing
All (except exempt)
6 months
Premarket Review
III Begin - 12 monthsComplete - within 5 years
II Begin – 5 years (after completion of class III reviews)
Complete - within 9 years
65
LDT Notification Guidance
Notification to FDA Who: manufacturer of any LDT – no exceptions What: must notify FDA and provide basic
information about LDT Data will be used to classify LDTs Will be made publically available on FDA
website Enforcement discretion depends on notification
When: Within 6 months of final Framework Guidance Prior to significant changes to notified LDTs
How: FDA websiteklgates.com 66
Proposed Regulation of LDTs – Practice Tips
Increased FDA regulation of LDTs is coming Question is when and how much
Comment period on draft guidances ends 1/30/15 Will take FDA time to review and address
comments In 2015, prepare for:
Notification to FDA Registration and listing (unless exempt) Look for draft classification guidance
In 2016, prepare for: Premarket review of prioritized class III LDTs
klgates.com 67
Ellen L. Darling
Orange County Office
+1.949.623.3540
Carol Pratt
Portland Office
+1.503.226.5762
Questions?
klgates.com 68